NuVasive (NUVA) Receives Conditional Approval from FDA to Begin Clinical Trial Enrollment for NeoDisc

NuVasive, Inc. (Nasdaq: NUVA) announced it has received conditional approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin clinical trial enrollment of its NeoDisc cervical disc replacement device.

The clinical trial is a prospective, randomized, controlled, multi-center trial to evaluate the safety and efficacy of NeoDisc by comparing the outcomes of patients to traditional anterior cervical discectomy and fusion. The Company expects to begin enrolling patients in the trial by the fourth quarter of 2006 with a follow-up period of two years.

You May Also Be Interested In

• Jazz Pharmaceuticals (JAZZ) Phase 3 Trial Evaluating Nabiximols Oromucosal Spray Did Not Meet Primary Endpoint
• MeiraGTx Holdings plc (MGTX) Reports Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision
• Sutro Biopharma (STRO) and Astellas Enter Global Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)